Abstract | AIM: METHODS: Eleven patients presenting cardiogenic shock (N=6) or scheduled for high-risk percutaneous revascularization (N=5) were evaluated. The Impella pump was successfully implanted in all patients, except one. When implanted, the device was correctly positioned in the left ventricle and remained in a stable position. RESULTS: Bleedings occurred in 7 patients (5 of them presented cardiogenic shock), while renal failure and severe thrombocytopenia were observed in 4 and 1 patients respectively, all with cardiogenic shock. During high-risk procedures, the Impella pump succeeded in obtaining hemodynamic stability, while in only two patients with cardiogenic shock the device determined a significant improvement of hemodynamic variables. All elective patients and two patients with cardiogenic shock were discharged from the hospital and were still alive at 30-day follow-up. CONCLUSION: These data, although preliminary due to the limited sample size, demonstrated the feasibility, safety and efficacy of the Impella Recover LP 2.5 during high-risk percutaneous procedures, even though the benefits of prophylactic deployment of such a system have to be further investigated. The use of Impella Recover LP 2.5 in patients with cardiogenic shock is feasible and safe, however it maybe insufficient in reversing an advanced cardiogenic shock which, probably, has to be treated with more powerful left ventricular assist devices.
|
Authors | S Vecchio, T Chechi, G Giuliani, A Lilli, L Consoli, G Spaziani, F Giannotti, M Margheri |
Journal | Minerva cardioangiologica
(Minerva Cardioangiol)
Vol. 56
Issue 4
Pg. 391-9
(Aug 2008)
ISSN: 0026-4725 [Print] Italy |
PMID | 18614983
(Publication Type: Journal Article)
|
Topics |
- Acute Coronary Syndrome
(surgery)
- Aged
- Aged, 80 and over
- Angioplasty, Balloon, Coronary
- Feasibility Studies
- Heart-Assist Devices
- Humans
- Male
- Middle Aged
- Risk Factors
- Shock, Cardiogenic
(surgery)
|